Clonal origin and expansions in neoplasms: biologic and technical aspects must be considered together.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Pathological bases for a robust application of cancer molecular classification.International journal of molecular sciences · 2015
   Review
2. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.International journal of molecular sciences · 2012
   Review

Corrections and comments

• Comment on
  Molecular clonality of in-transit melanoma metastasis.2001

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as